Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Matthew J. Frigault, Richard T. Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L. Phillips, Lea Burke, Jing Lei, Michael Pratta, Rodica Morariu-Zamfir, John F. DiPersio

Blood blood.2024026586.

https://doi.org/10.1182/blood.2024026586

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluation of Itacitinib Impact on TNFα Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches

Olga Ivanova, Michael Pratta, Ivan Azarov, Kirill Zhudenkov, Yuri Kosinsky, Kirill Peskov, Xuejun Chen, Jennifer Sheng

Blood (2024) 144 (Supplement 1): 7129.

https://doi.org/10.1182/blood-2024-199649

Published: 2024

Journal Articles

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Michael Pratta, Angelina Volkova, Maureen Bleam, Rodica Morariu-Zamfir, Beth Rumberger, Stephen Douglass, Susan H. Smith, Valkal Bhatt, John Galvin, Annie Im, Sophie Paczesny, Kirk R. Schultz, Steven Z. Pavletic

Blood (2023) 142 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2023-174955

Published: 2023

Journal Articles

Axatilimab Ameliorates Inflammation and Fibrosis By Targeting Macrophages in a Preclinical Model of Chronic GVHD

Anamika Bajpai, Linda Solomon, James Kearns, Angelina Volkova, Michael Pratta, Susan H. Smith

Blood (2023) 142 (Supplement 1): 2540.

https://doi.org/10.1182/blood-2023-181746

Published: 2023

Journal Articles

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael Pratta, Lea Burke, John F. DiPersio, Richard T. Maziarz, Patricia Feldman, Teresa Brodeur, Cynthia Timmers, Olga Ivanova, April Barbour, Rodica Morariu-Zamfir, Matthew Frigault

Blood (2022) 140 (Supplement 1): 10350–10351.

https://doi.org/10.1182/blood-2022-169382

Published: 2022

NARROW

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Evaluation of Itacitinib Impact on TNFα Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Axatilimab Ameliorates Inflammation and Fibrosis By Targeting Macrophages in a Preclinical Model of Chronic GVHD

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Email alerts

ASH Publications

American Society of Hematology

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Evaluation of Itacitinib Impact on TNFα Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Axatilimab Ameliorates Inflammation and Fibrosis By Targeting Macrophages in a Preclinical Model of Chronic GVHD

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only